Skip to main content
. Author manuscript; available in PMC: 2013 Sep 6.
Published in final edited form as: Cancer Discov. 2012 Sep 6;2(9):798–811. doi: 10.1158/2159-8290.CD-12-0112

Figure 4. SCLC and LCNEC are sensitive to PARP inhibition in vitro.

Figure 4

(A) Cell were treated with 0.1, 1, and 10 μM AZD2281 for 24 hrs, cell extracts collected, and poly ADP ribose (PAR) levels evaluated by ELISA to assess PARP1 activity. (B) IC50 values for lung cancer cell lines treated with AZD2281 for 5 days. (C) Lung and breast cancer cells were treated with increasing concentrations of AZD2281 or AG014699 for 14 days. (D) PARP1 and EZH2 knockdown by siRNA effect SCLC proliferation.